New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2014
11:09 EDTMYL, KSU, GGB, TEVAOptions with increasing implied volatility: GGB MYL TEVA KSU
News For GGB;MYL;TEVA;KSU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 22, 2015
10:14 EDTKSUKansas City Southern could yield synergies for Canadian National, says Cowen
Cowen said Canadian National (CNI) has been increasing its presence and service offerings in the U.S. Gulf coast and a merger with Kansas City Southern (KSU) could increase competitiveness and result in substantial revenue synergies. The firm said Kansas City Southern trades at a 25% premium to the rail group and any merger would involve a great amount of political risk and has no reason to believe the company is contemplating such a move.
June 21, 2015
19:53 EDTTEVA, MYLMylan CEO says Teva's 4.61% stake may be 'illegal,' Bloomberg reports
Subscribe for More Information
June 19, 2015
08:30 EDTTEVA, MYLTeva completes purchase of 4.61% interest in Mylan
Subscribe for More Information
07:23 EDTTEVATeva data quite strong, says Bernstein
After Teva (TEVA) announced data for its TEV-48125 drug in episodic migraine, Bernstein notes that the drug met its primary and secondary endpoints. The firm says that the reduction in migraine days of Teva's drug appears to be higher than what Amgen (AMGN) and Lilly (LLY) have shown. The firm continues to see the migraine treatments from Teva and Alder as better than those from Lilly and Amgen.
05:47 EDTMYLStocks with implied volatility movement; MYLCMG
Subscribe for More Information
June 18, 2015
17:05 EDTTEVANovartis announces U.S. launch of Glatopa
Sandoz, a Novartis (NVS) company, announced the U.S. launch of Glatopa, the first generic version of Teva's (TEVA) Copaxone 20 mg/ml one-time-daily multiple sclerosis therapy.
15:41 EDTMYL, TEVATeva tender offer for Mylan likely imminent, says Citi
Citi said Teva (TEVA) is likely to build up a 4.6% stake in Mylan (MYL) by today and that a formal tender offer is likely coming soon. An official bid could come with a provision requiring board changes and a tender will likely trigger a "poison pill" by Mylan, the firm added. Citi has a Buy rating and $70 price target on Teva shares.
12:51 EDTTEVATeva guidance assumed launch of Copaxone generic, says BMO Capital
Subscribe for More Information
11:57 EDTTEVA, MYLMylan comments on ruling by appeals court on Copaxone patent
Subscribe for More Information
11:54 EDTTEVA, MYLAppeals court invalidates Teva patent claim related to Copaxone
Subscribe for More Information
10:41 EDTTEVAMomenta reports CAFC decision to invalidated remanded Teva patent
Subscribe for More Information
10:01 EDTMYLOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:11 EDTTEVAAlexza Pharmaceuticals amends Adasuve commercial partnership agreements
Subscribe for More Information
08:34 EDTTEVATeva to present new data from Phase 2b migraine prevention studies at AHS
Subscribe for More Information
08:02 EDTTEVATeva, Microchips Biotech announce partnership agreement
Subscribe for More Information
07:46 EDTMYLMylan initiated with a Buy at BTIG
Subscribe for More Information
07:36 EDTTEVAReceptos remains an attractive takeover candidate, says Leerink
Subscribe for More Information
06:09 EDTTEVA, MYLTeva raises stake in Mylan to 4.3%, Globes reports
Subscribe for More Information
June 17, 2015
11:08 EDTKSUOptions with increasing implied volatility
Subscribe for More Information
07:12 EDTTEVANeurocrine price target raised to $87 from $63 at Piper Jaffray
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use